New hope for tough lung cancer: experimental drug takes on KRAS mutation
NCT ID NCT07601048
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new drug called HRS-7058 against other KRAS G12C inhibitors in 450 adults with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to standard treatments. The study compares how well HRS-7058 works and its safety, aiming to find a better option for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-7058 (a KRAS G12C inhibitor)
What this could lead to
If successful, this could offer a new treatment option for people with a specific type of advanced lung cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not be more effective or safer than existing KRAS G12C inhibitors, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WHO HAVE FAILED STANDARD TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Contact